SAVA
Cassava Sciences, Inc. [SAVA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SAVA Stock Summary
Top 10 Correlated ETFs
SAVA
Top 10 Correlated Stocks
SAVA
In the News
SAVA Financial details
Company Rating
-
Market Cap
983.37M
Income
-94.59M
Revenue
2.35M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
29
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
-11.07
Forward P/E
-
PEG
-4.33
P/S
-562087.03
P/B
6.5
P/C
-
P/FCF
-12.48
Quick Ratio
8.25
Current Ratio
8.62
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.26
EPS next Y
-
EPS next Q
-
EPS this Y
28.89%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-18.03%
-
-
-
-
SMA20
91.24%
SMA50
86.1%
SMA100
96.68%
Inst Own
-
Inst Trans
-
ROA
-53%
ROE
-48%
ROC
-0.67%
Gross Margin
100%
Oper. Margin
5805333%
Profit Margin
5055389%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
12.32-32.1
52W High
-86.56%
52W Low
-64.17%
RSI
64.92
Rel Volume
4.24
Avg Volume
677.96K
Volume
2.88M
Perf Week
8.04%
Perf Month
99.07%
Perf Quarter
170.44%
Perf Half Y
207.14%
-
-
-
-
Beta
-0.399
-
-
Volatility
0.28%, 0.85%
Prev Close
-4.87%
Price
4.3
Change
-9.09%
Company Profile
- Volume Average 677.96K
- Market Capitalization 983.37M
- Employee 29
- CEO Mr. Remi Barbier
- Headquarters Austin,TX,US
- IPO Date 2000-07-14
-
Website
https://www.cassavasciences.com 
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
